Pharmaceutical company GlaxoSmithKline is planning a commercial reboot to streamline their budget, potentially generating budget savings of 20%.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
Going against industry trend of backing out of the neuroscience field, is Celgene, who is about to put down a potential $2.2 million to gain options on three Prothena drug candidates.
Healthcare tech startup Theranos was riding high back in 2014. But when a reporter raised questions, its media reps circled the wagons.
Chinese pharmaceutical companies are proving their place in the US generic drugs market, with a rising number of approvals for copycat medicines almost doubling in the past year.
FDA Commissioner, Scott Gottlieb has critiqued health insurers, as he homes in on the increasingly popular target of rebates in the drug pricing debate.
Novartis is preparing to make some big changes to its structure following the departure of its operations chief, and a desire to aim for big digital things.
A life sciences expert has warned that obtaining CRISPR IP rights is expected to become a lot more difficult in the near future.
FDNA has announced a Genomics Collaborative, with the aim of developing new precision medicine approaches that builds on partnerships already underway in the research community.
Google has announced a partnership with WuXi NextCODE, with the aim of enhancing its comprehensive genomics capabilities.